GSK PLC (GSK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-23
$50.75-0.90%
Close 2026-10-23 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-23
Research Workspace
Put GSK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near $5.12 in FY27: Direct metric needs a verified mapping.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskGSK’s case rests on its product pipeline, with recent cancer-trial advances supporting launches. No earnings history is available to confirm revenue growth or a latest result. The desk has no valuation multiple or peer comparison to show what prices in. The latest recorded surprise was a 7.1% beat, with a 13% miss probability. The named risk is pressure on the FY27 EPS pillar near $5.12. That metric still needs verified mapping, and the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-23. GSK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering GSK (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare GSK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GSK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put GSK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Licensing deal expands GSK’s oncology pipeline, though its overall thesis impact is incremental.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-23. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Acquisition supports GSK's pipeline expansion in oncology.
Positive trial results support future product launch potential.
Positive data enhances market confidence in Jideytro.
Successful trial enhances GSK's product pipeline potential.
Positive data on mRNA flu vaccine supports product development.
Pipeline developments support future product launches.
Advancing to Phase III is a significant milestone for GSK.
